Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Is Illumina Still The Gamechanger In Genomic Sequencing?
07:37am, Wednesday, 05'th Oct 2022 Investing.comNatera to Participate in Upcoming Investor Conferences
01:32pm, Tuesday, 06'th Sep 2022
AUSTIN, Texas , Sept. 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, ch
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
02:34pm, Thursday, 25'th Aug 2022 Benzinga
Upgrades
According to Goldman Sachs, the prior rating for FREYR Battery (NYSE:FREY) was changed from Neutral to Buy. In the second quarter, FREYR Battery showed an EPS of $0.24, compared to $0.04 from
Natera, Inc. (NTRA) CEO Steve Chapman on Q2 2022 Results - Earnings Call Transcript
06:40pm, Saturday, 06'th Aug 2022
Natera, Inc. (NASDAQ:NTRA ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Mosh
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
11:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 47% Upside in Natera (NTRA): Here's What You Should Know
01:55pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
The consensus price target hints at a 47.5% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natera Announces Second Quarter 2022 Earnings Conference Call
01:13pm, Monday, 01'st Aug 2022
AUSTIN, Texas , Aug. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 3
Bull of the Day: Illumina (ILMN)
09:20am, Monday, 01'st Aug 2022 Zacks Investment Research
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
Earnings Preview: Natera (NTRA) Q2 Earnings Expected to Decline
02:02pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Natera (NTRA) Have the Potential to Rally 76% as Wall Street Analysts Expect?
01:55pm, Monday, 18'th Jul 2022 Zacks Investment Research
The consensus price target hints at a 75.6% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Seven reasons the beleaguered biotech sector is now a 'buy'
11:33am, Saturday, 18'th Jun 2022 MarketWatch
Investors ought to take advantage of low prices for a long-term view.
Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting
08:33am, Tuesday, 31'st May 2022
NSCLC: ctDNA data in stage I-III patients showed 82% detection pre-treatment and was able to identify 100% of relapses prior to radiographic imaging (5.4 mo lead time) Breast Cancer: Data from the
8 Analysts Have This to Say About Natera
09:44pm, Monday, 16'th May 2022 Benzinga
Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
6
0
0
0
Last 30D
0
1
Natera, Inc.'s (NTRA) CEO Steve Chapman on Q1 2022 Results - Earnings Call Transcript
03:06am, Sunday, 08'th May 2022
Natera, Inc. (NASDAQ:NTRA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshke
